Now I have a good sense of the calibration landscape. Let me finalize my assessment.

**Calibration anchors summary:**

| Anchor | Path | Avg Score | Round | Comparison |
|--------|------|-----------|-------|------------|
| Systematic Review of LLMs | 8QTpYC4smR | 1.00 | R1 | Weak survey; our paper is stronger |
| Jailbreaking LLMs | 5kMwiMnUip | 1.40 | R1 | Non-technical; our paper is much stronger |
| Biomedical KG Construction | K1bv86Uvbp | 3.00 | R1 | Similar domain, methodological concerns; comparable |
| From Counseling to Mind Map | zPxlHOLxmh | 2.00 | R1 | LLM application paper; our paper is stronger |
| EchoQA | JiWlVYB4rh | 3.00 | R1 | Medical benchmark paper; comparable |
| Enhancing Clinical Note Summarization | MEztAJjcYZ | 4.25 | R1 | Very similar domain (clinical summarization); comparable quality, rejected |
| Revisiting Scaling Effects of LLMs | jgVqCCg5XX | 4.00 | R1 | Very relevant (scaling in medical domain); comparable, rejected |
| Do Current LLMs Master Clinical Knowledge | gYcft1HIaU | 4.33 | R1 | Clinical knowledge evaluation; comparable |
| Enhancing Small Medical Learners | ztpy1gsUpT | 6.00 | R1 | Small medical LMs; stronger methodology, accepted |
| Reliable Evaluation of LLM Medical Knowledge | TXfzH933qV | 7.00 | R1 | Medical evaluation framework; stronger contribution |

**Round 1 bracket:** Between 3.0 and 4.5 (reject band). The paper's core contribution (collapse analysis, scaling benchmarks) places it above the 2-3 range papers that have weaker methodology and less insight. But the unfair comparison flaw—where only small models get LoRA fine-tuning while large models are evaluated zero/few-shot only—is a structural problem that the ~4.0-4.25 rejected papers also suffer from (e.g., the scaling effects paper had similar methodology concerns). The paper does not reach the 6.0 accept band because those papers have fairer comparisons and stronger methodology.

**Final score: 4.0** — This places it in the reject band alongside comparable clinical NLP papers that had meaningful contributions but methodological flaws preventing acceptance. The paper has genuine empirical findings (collapse threshold, multimodal vs. unimodal contrast) but its headline claim rests on an unfair comparison.

---

## Summary
This paper benchmarks small language models (≤3B parameters) against larger medically-adapted LLMs (7–8B) on clinical text summarization (MeQSum) and radiology report generation (MIMIC-CXR), using zero-shot, few-shot, and LoRA fine-tuning. It introduces a "Collapse Analysis" measuring Task Adherence, Hallucination Rate, Concept Recall, and Prompt Robustness across model scales, identifying a safety collapse threshold around 1B parameters where hallucination rates spike dramatically.

## Strengths
- **Empirical safety collapse identification:** Table 3 reveals a non-linear degradation pattern—hallucination rates hold steady at 2–3% down to 1.7B parameters but spike to 18.3% (SmolLM2-360M) and 75% (Gemma-3-270M). This threshold finding is genuinely useful for clinical deployment decisions.
- **Task-dependent scaling insight:** The contrast between text summarization (where fine-tuned small LMs perform well) and radiology report generation (where small VLMs lag behind large VLMs, per Table 4) reveals that visual reasoning demands fundamentally different capacity than text-only tasks.
- **Multi-prompt evaluation design:** Results averaged across five prompt templates (Section 3.1) treat prompt selection as an experimental variable, mitigating a known confound in small model evaluation.
- **Qualitative VLM failure analysis:** Figure 4 provides concrete clinical examples showing fine-tuned Qwen 2.5-VL introducing incorrect findings (e.g., "small right pleural effusion" absent from ground truth), illustrating real clinical risk.

## Weaknesses

### Fatal
None.

### Major
- **Unfair comparison underpins the headline claim.** The central finding—that fine-tuned small LMs "outperform large LMs across every metric" (Section 4, Finding 1, Figure 3)—is built on a comparison where only small models received LoRA fine-tuning. Figure 3 shows large models (BioMistral-7B, Med-LLaMA-8B, OpenBioLLM-8B) evaluated only with ICL (zero/few-shot), with "-" for all LoRA entries. The same asymmetry applies to VLMs in Table 4 (small VLMs fine-tuned, large VLM baselines not). Without fine-tuning the large baselines, the paper demonstrates that fine-tuning helps (already well-known), not that small models can match large ones. This is the paper's most consequential flaw, as it invalidates the core conclusion as stated.

- **Collapse Analysis methodology is entirely undefined.** Table 3 presents values for Task Adherence, Hallucination Rate, Concept Recall, Robustness, and Readiness Score, but the paper provides no description of how any of these are measured. Section 3.1 (lines 114) states the analysis was "conducted" and describes the results, but never defines the measurement procedure. What constitutes a "hallucination"? How is "Task Adherence" scored (0-1 scale)? Is "Concept Recall" the same as MEDCON or something else? How is the composite "Readiness Score" computed? Without this, the paper's most novel contribution—the safety threshold claim—is unverifiable and unreproducible.

### Minor
- **No human evaluation despite safety-oriented deployment claims.** The paper makes "minimum viable scale for safe, on-premise clinical deployment" recommendations based entirely on automatic metrics (BLEU, ROUGE-L, BERTScore, MEDCON). The paper itself acknowledges in Section 2 (lines 49-51) that "physicians often prefer larger models... even when metric scores are similar." This tension is identified but unresolved.
- **"MeQ-Small corpus" (line 231) is referenced but never defined.** It is unclear whether this is a training split of MeQSum or a different dataset. The train/test split details are absent.
- **No statistical rigor.** No error bars, confidence intervals, standard deviations, multiple random seeds, or statistical significance tests are reported anywhere in the paper, which is notable for a benchmark study making deployment recommendations.
- **Broken table reference.** Line 219 states "From Table ?? we can infer..." indicating an unresolved reference, likely to a pre-fine-tuning VLM results table.

### Trivial
- **"SmolLM3-3B" in Table 3 is not mentioned in Table 1** or elsewhere in the model descriptions, creating an inconsistency in the experimental setup documentation.
- **Abstract overstates scope.** Claims to evaluate models "across a broad spectrum of parameter scales," but the evaluation involves only 3 small vs. 3 large LMs and 2 small vs. 2 large VLMs.

## Nice-to-Haves
- Fine-tuning the large medical LLMs with the same LoRA setup would transform this from an unfair comparison into a genuinely informative efficiency analysis (cost-performance Pareto frontier).
- Per-prompt variance or breakdown in Table 2 would clarify whether averaging masks extreme prompt sensitivity.
- A small-scale human evaluation (50–100 samples rated by clinicians) would substantially strengthen clinical deployment claims.
- Defining each Collapse Analysis dimension in a methodology subsection would make the most novel contribution usable by the community.

## Removed Points
These points are flagged to be removed, treat them with caution:
- **LoRA hyperparameters not reported:** The appendix was stripped from the parsed paper; hyperparameters (rank, alpha, learning rate, epochs, adapted modules) may be present in the original appendix.
- **Missing appendix content:** Per rules, the parser strips appendix sections from all papers.
- **Table 1 vs. Table 3 inconsistency for model sizes:** Table 1 lists model families (not individual sizes), so the SmolLM2 sub-model variants in Table 3 are not actually inconsistent—they are members of the listed families.

## Novel Insights
The identification of a non-linear "safety collapse" threshold around 1B parameters—where hallucination rates remain stable (2–3%) down to 1.7B but spike to 18–75% below ~400M—is a genuinely useful empirical contribution for clinical deployment, even if the measurement methodology behind these numbers needs much more detail. The finding that text summarization and radiology report generation have fundamentally different scaling requirements is also an important practical insight.

## Suggestions
- Fine-tune the large baselines (BioMistral-7B, Med-LLaMA-8B, OpenBioLLM-8B) with the same LoRA configuration on the same data, and report their results alongside the small models. This is the single most critical missing experiment.
- Add a dedicated methodology subsection defining each Collapse Analysis dimension, its measurement procedure, and the Readiness Score computation.
- Resolve the "Table ??" reference and define the "MeQ-Small corpus."
- Add confidence intervals or variance measures for the benchmark results.
- Consider even a small human evaluation to support deployment safety claims.

MY FINAL SCORE: <score>4.0</score>
MY FINAL DECISION: <decision>Reject</decision>